Breaking News

Tweet TWEET

Pfizer Sues Torrent Pharma to Block Generic Viagra Sales

Pfizer Inc. sued Torrent Pharmaceuticals Ltd. (TRP) in a bid to block sales of a generic version of erectile-dysfunction drug Viagra while the largest U.S. drugmaker’s patent is still in effect.

Torrent is seeking approval from the U.S. Food and Drug Administration for generic Viagra, also known as sildenafil citrate, before Pfizer’s U.S. patent expires on Oct. 22, 2019, according to a complaint filed in federal court in Manhattan.

Pfizer reported $1.88 billion in Viagra sales in 2013, or 3.6% of total revenue, according to Bloomberg data. Pfizer has sued other drug companies in the same court over similar claims.

The company seeks an order permanently barring Ahmedabad, India-based Torrent, its officers, agents and employees from “making, using, selling, selling, marketing, distributing or importing” the allegedly infringing drug.

Pfizer and Teva Pharmaceuticals USA Inc. reached a settlement that permits the Israeli drugmaker to market a generic version of Viagra in the U.S. on Dec. 11, 2017, or earlier under certain circumstances, New York-based Pfizer said in December.

The case is Pfizer Inc. (PFE) v. Torrent Pharmaceuticals Ltd., 14-cv-01831, U.S. District Court, Southern District of New York (Manhattan).

To contact the reporter on this story: Peter Blumberg in San Francisco at pblumberg1@bloomberg.net

To contact the editors responsible for this story: Michael Hytha at mhytha@bloomberg.net Peter Blumberg, Andrew Dunn

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.